Summary: Spinal cord injuries often cause long-term paralysis because nerve fibers have limited ability to regrow. A new study presents an alternative strategy: rather than trying to regenerate severed fibers, researchers used a designer protein called hyper-interleukin-6 (hIL-6) to rewire intact neural pathways and restore function.
By turning the brain’s motor cortex into a local source of therapeutic protein, the team promoted the growth of collateral nerve branches from uninjured axons. This circuit remodeling enabled paralyzed mice to recover coordinated walking.
Key Facts
- The hIL-6 messenger: Hyper-interleukin-6 is a potent signaling protein that can directly engage neurons. In the experiments, it was produced in neurons after injection of an AAV2 viral vector into the motor cortex, the brain’s movement control center.
- Transneuronal transport: Once produced, hIL-6 travels down existing axons to deeper motor centers in the brainstem, where it stimulates downstream neurons important for locomotion.
- Plasticity over regeneration: The treatment does not shrink the lesion or replace dead cells. Instead, it triggers circuit plasticity: intact axons sprout new collateral branches that form detours around the injured area.
- Restored gait: Mice treated with hIL-6 showed markedly improved walking and recovered coordinated gait patterns, while untreated controls remained largely paralyzed.
- The role of serotonergic neurons: The therapeutic effect depended on brainstem serotonergic neurons. When those neurons were selectively eliminated, the recovery disappeared, indicating these descending pathways are central to regained function.
Source: University of Cologne
Spinal cord contusion injuries—where some fibers are compressed and others remain intact—typically cause persistent motor and sensory deficits. Current treatments can only partially improve recovery. The research group led by Professor Dietmar Fischer at the Institute of Pharmacology II, University Hospital Cologne, explored a different route: enhancing the nervous system’s own ability to rewire around damage.
The study, titled “Transneuronal cytokine delivery promotes functional recovery across spinal cord contusion severities via descending circuit plasticity,” was accepted for publication in Neurobiology of Disease and made available online in June 2026. Using an AAV2 vector to express hIL-6 in motor cortex neurons, the team activated signaling pathways in both injured and spared neurons. The neurons themselves transported the cytokine along intact axons to subcortical motor centers, producing a targeted stimulation of downstream circuits.
Rather than relying only on regrowth across the lesion, this approach exploits surviving connections. hIL-6 induced the formation of collateral sprouts from intact descending fibers that bypassed the damaged spinal segment and reconnected with motor circuits below the lesion. As a result, treated animals showed significant functional gains without measurable changes in lesion size or overall neuronal loss.
Across mouse models of mild, moderate, and severe spinal cord contusion, AAV2-hIL-6 treatment consistently improved locomotor outcomes compared with control animals that received AAV2-GFP. The researchers observed increased number and length of descending serotonergic axons in the lumbar spinal cord, a change that correlated with the recovery of coordinated stepping. Selective ablation of serotonergic neurons abolished the behavioral improvements, confirming their essential role in the restored function.
Although AAV2-hIL-6 modestly reduced retraction of corticospinal tract axons, it did not promote axon growth past the lesion, implying corticospinal regeneration was not necessary for recovery. Instead, intracortical delivery of hIL-6 drives remodeling of spared descending circuits and functional restoration across contusion severities.
The authors emphasize that while results in mice are promising, translation to human patients requires further work. Key questions remain about long-term safety of the viral vector, appropriate dosing for the larger human nervous system, and potential side effects. Additional preclinical studies are needed before clinical trials can be considered.
Key Questions Answered:
A: Imagine a closed highway. Instead of rebuilding the collapsed bridge, hIL-6 encouraged the nervous system to build alternate routes using intact roads. Collateral sprouts form detours that route movement signals around the injury, restoring communication with spinal circuits that control walking.
A: Injecting the vector into the motor cortex turns the region that initiates movement into a production hub. Neurons then transport hIL-6 along their axons into the brainstem and spinal cord, precisely targeting the descending circuits responsible for locomotion.
A: While the mouse data are encouraging, clinical application is still a number of steps away. Researchers must establish long-term safety of the viral approach, define safe and effective doses for humans, and evaluate side effects before human trials can begin.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The original journal paper was reviewed in full.
- Additional context was added by the editorial staff.
About this spinal cord injury and genetics research news
Author: Eva Schissler
Source: University of Cologne
Contact: Eva Schissler, University of Cologne
Image: Image credited to Neuroscience News
Original Research: Open access. “Transneuronal cytokine delivery promotes functional recovery across spinal cord contusion severities via descending circuit plasticity” by Marco Leibinger, Igor Moskaliov, Chinonso-John Ani, Dalia Halawani, and Dietmar Fischer. Neurobiology of Disease. DOI: 10.1016/j.nbd.2026.107399
Abstract
Transneuronal cytokine delivery promotes functional recovery across spinal cord contusion severities via descending circuit plasticity
Spinal cord injury often results in lasting motor and sensory deficits; complete injuries cause loss of function below the lesion, while incomplete injuries leave partial connectivity intact. Intracortical delivery of an AAV2 vector encoding the designer cytokine hIL-6 enhances recovery after complete spinal cord injury by transneuronally stimulating raphe nuclei. This study confirms that AAV2-hIL-6 activates subcortical neurons in the medulla and shows that the same strategy improves recovery in clinically relevant mouse contusion models of mild, moderate, and severe injury.
Across all severities tested, AAV2-hIL-6 significantly improved locomotor function compared with controls treated with AAV2-GFP. Lesion size and neuronal loss correlated with contusion severity and were not changed by the treatment; nonetheless, AAV2-hIL-6 robustly increased the number and length of descending serotonergic axons in the lumbar spinal cord. Selective removal of serotonergic neurons abolished the functional gains, confirming their essential role in sensorimotor recovery. Although AAV2-hIL-6 reduced corticospinal tract axon retraction, it did not induce axon growth beyond the lesion, indicating corticospinal regeneration was not necessary for recovery.
In summary, intracortical AAV2-hIL-6 delivery drives remodeling of spared descending circuits and promotes functional restoration across differing contusion severities, highlighting its potential as a therapeutic strategy for spinal cord injuries that preserve some neural pathways.